Novartis AG, Roche’s Xolair Blunts Asthma Attacks in Children in U.S. Cities

Bloomberg -- Xolair, sold by Novartis AG (NOVN) and Roche Holding AG (ROG), improved treatment of asthma for inner-city children and young adults, according to a U.S.-funded study.

MORE ON THIS TOPIC